A patent review of glucokinase activators and disruptors of the glucokinase-glucokinase regulatory protein interaction: 2011-2014

Expert Opinion on Therapeutic Patents

Volumn 24, Issue 8, 2014, Pages 875-891

  Filipski, Kevin J ^a   Pfefferkorn, Jeffrey A ^a  

^a PFIZER INC   (United States)

Author keywords

Glucokinase; Glucokinase activator; Glucokinase regulatory protein

Indexed keywords

1,2,4 ARYL CENTERED GLUCOKINASE ACTIVATOR; 1,3,5 ARYL CENTERED GLUCOKINASE ACTIVATOR; AMINO ACID BASED GLUCOKINASE ACTIVATOR; ANTIDIABETIC AGENT; CARBON CENTERED GLUCOKINASE ACTIVATOR; ENZYME ACTIVATOR; GLUCOKINASE; GLUCOKINASE ACTIVATOR; GLUCOKINASE GLUCOKINASE REGULATORY PROTEIN DISRUPTOR; THIOPHENE CENTERED GLUCOKINASE ACTIVATOR; UNCLASSIFIED DRUG; UREA CENTERED GLUCOKINASE ACTIVATOR; CARRIER PROTEIN; GLUCOKINASE REGULATORY PROTEIN; GLUCOSE;

DRUG EFFICACY; ENZYME ACTIVITY; HUMAN; HYPOGLYCEMIA; NON INSULIN DEPENDENT DIABETES MELLITUS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PROTEIN PROTEIN INTERACTION; REVIEW; RISK FACTOR; ANIMAL; CHEMICALLY INDUCED; DIABETES MELLITUS, TYPE 2; DRUG DESIGN; DRUG EFFECTS; ENZYME ACTIVATION; METABOLISM; PATENT; PATHOPHYSIOLOGY;

ANIMALS; CARRIER PROTEINS; DIABETES MELLITUS, TYPE 2; DRUG DESIGN; ENZYME ACTIVATION; GLUCOKINASE; GLUCOSE; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; PATENTS AS TOPIC;

EID: 84904622340     PISSN: 13543776     EISSN: 17447674     Source Type: Journal    
DOI: 10.1517/13543776.2014.918957     Document Type: Review

References (118)

1. World Health Organization Diabetes Fact Sheet. 2013. Available from:http://www.who.int/mediacentre/factsheets/fs312/en/[Last accessed 3 March 2014]
2. Matschinsky FM. Assessing the potential of glucokinase activators in diabetes therapy. Nat Rev Drug Discov 2009;8(5):399-416
3. Fyfe MCT, Procter MJ. Glucokinase activators as potential antidiabetic agents possessing superior glucose-lowering efficacy. Drugs Future 2009;34:641-53
4. Matschinsky FM, Magnuson MA. editors. Glucokinase and glycemic disease: from basics to novel therapeutics. S. Karger AG; Basel, Switzerland: 2004
5. Matschinsky FM. A lesson in metabolic regulation inspired by the glucokinase glucose sensor paradigm. Diabetes 1996;45:223-41
6. Del Guerra S, Lupi R, Marselli L, et al. Functional and molecular defects of pancreatic islets in human type 2 diabetes. Diabetes 2005;54:727-35
7. Agius L. Glucokinase and molecular aspects of liver glycogen metabolism. Biochem J 2008;414(1):1-18
8. Anderka O, Boyken J, Aschenbach U, et al. Biophysical characterization of the interaction between hepatic glucokinase and its regulatory protein: impact of physiological and pharmacological effectors. J Biol Chem 2008;283(46):31333- 40
9. Pautsch A, Stadler N, Lohle A, et al. Crystal structure of glucokinase regulatory protein. Biochemistry 2013;52(20):3523-31
10. Choi JM, Seo MH, Kyeong HH, et al. Molecular basis for the role of glucokinase regulatory protein as the allosteric switch for glucokinase. Proc Natl Acad Sci USA 2013;110(25):10171-6
11. Kaminski MT, Schultz J, Waterstradt R, et al. Glucose-induced dissociation of glucokinase from its regulatory protein in the nucleus of hepatocytes prior to nuclear export. Biochim Biophys Acta 2013;1843(3):554-64
12. Zelent B, Raimondo A, Barrett A, et al. Analysis of the co-operative interaction between the allosterically regulated proteins GK and GKRP using tryptophan fluorescence. Biochem J 2014;459(3):551-64
13. Cullen KS, Agius L, Al-Oanzi ZH, et al. Glucagon induces translocation of glucokinase from the cytoplasm to the nucleus of hepatocytes by transfer between 6-phosphofructo 2-kinase/fructose 2, 6-bisphosphatase-2 and the glucokinase regulatory protein. Biochim Biophys Acta 2014;1843(6):1123-34
14. Basu A, Basu R, Shah P, et al. Effects of type 2 diabetes on the ability of insulin and glucose to regulate splanchnic and muscle glucose metabolism: evidence for a defect in hepatic glucokinase activity. Diabetes 2000;49(2):272-83
15. Basu A, Basu R, Shah P, et al. Type 2 diabetes impairs splanchnic uptake of glucose but does not alter intestinal glucose absorption during enteral glucose feeding: additional evidence for a defect in hepatic glucokinase activity. Diabetes 2001;50(6):1351-62
16. Caro JF, Triester S, Patel VK, et al. Liver glucokinase: decreased activity in patients with type II diabetes. Horm Metab Res 1995;27:19-22
17. Fujimoto Y, Torres TP, Donahue EP, Shiota M. Glucose toxicity is responsible for the development of impaired regulation of endogenous glucose production and hepatic glucokinase in Zucker diabetic fatty rats. Diabetes 2006;55(9):2479-90
18. Dunn-Meynell AA, Routh VH, Kang L, et al. Glucokinase is the likely mediator of glucosensing in both glucose-excited and glucose-inhibited central neurons. Diabetes 2002;51(7):2056-65
19. Zelent D, Golson ML, Koeberlein B, et al. A glucose sensor role for glucokinase in anterior pituitary cells. Diabetes 2006;55(7):1923-9
20. Murphy R, Tura A, Clark PM, et al. Glucokinase, the pancreatic glucose sensor, is not the gut glucose sensor. Diabetologia 2009;52(1):154-9
21. Grimsby J, Sarabu R, Corbett WL, et al. Allosteric activators of glucokinase: Potential role in diabetes therapy. Science 2003;301(5631):370-3
22. Coghlan M, Leighton B. Glucokinase activators in diabetes management. Expert Opin Invest Drugs 2008;17:145-67
23. Filipski KJ, Stevens BD, Pfefferkorn JA. Glucokinase activators in development. In: Jones RM, editor. RSC drug discovery series No 27: new therapeutic stratagies for type 2 diabetes-small molecule approaches. Royal Society of Chemistry, Cambridge, UK; 2012. p. 88-108
24. Matschinsky FM. GKAs for diabetes therapy: why no clinically useful drug after two decades of trying? Trends Pharmacol Sci 2013;34:90-9
25. Pfefferkorn JA, Guzman-Perez A, Oates PJ, et al. Designing glucokinase activators with reduced hypoglycemia risk: discovery of N, N-dimethyl-5-(2- methyl-6-((5-methylpyrazin-2-yl)-carbamoyl)benzofuran-4-yloxy) pyrimidine-2-carboxamide as a clinical candidate for the treatment of type 2 diabetes mellitus. Med Chem Comm 2011;2(9):828-39
26. Hinklin RJ, Boyd SA, Chicarelli MJ, et al. Identification of a new class of glucokinase activators through structure-based design. J Med Chem 2013;56(19):7669-78
27. Pfefferkorn JA. Strategies for the design of hepatoselective glucokinase activators to treat type 2 diabetes. Expert Opin Drug Discov 2013;8(3):319-30
28. Ashton KS, Andrews KL, Bryan MC, et al. Small molecule disruptors of the glucokinase-glucokinase regulatory protein interaction: 1. Discovery of a novel tool compound for in vivo proof-of-concept. J Med Chem 2014;57(2):309-24
29. Sarabu R, Berthel SJ, Kester RF, Tilley JW. Glucokinase activators as new type 2 diabetes therapeutic agents. Expert Opin Ther Pat 2008;18(7):759-68
30. Sarabu R, Berthel SJ, Kester RF, Tilley JW. Novel glucokinase activators: a patent review (2008-2010). Expert Opin Ther Pat 2011;21(1):13-33
31. Filipski KJ, Futatsugi K, Pfefferkorn JA, Stevens BD. Glucokinase activators. Pharm Pat Anal 2012;1(3):301-11
32. Advinus Therapeutics Ltd. Acetamide compounds as glucokinase modulators and their preparation and use for treatment and prevention of glucokinase-mediated diseases. WO2012020357; 2012
33. Advinus Therapeutics Pvt. Ltd. Preparation of acetamide derivatives as glucokinase activators. WO2009047798; 2009
34. Advinus Therapeutics Ltd. Preparation of acetamide derivatives as glucokinase activators. US20120214735; 2012
35. Advinus Therapeutics Private Ltd. Preparation of acetamide compounds as glucokinase activators, their process and medicinal applications. EP2402327; 2012
36. Mitsubishi Tanabe Pharma Corp. Method for the preparation of (E)-hydroxyiminophenylacetic acid derivative. WO2011093423; 2011
37. Tanabe Seiyaku Co., Ltd. Preparation of oxime compounds as glucokinase activators. JP2010018526; 2010
38. Tanabe Seiyaku Co., Ltd. Oxime derivatives as glucokinase activating agents and their preparations, pharmaceutical compositions and use in the treatment of diabetes and related diseases. JP2008189659; 2008
39. Mitsubishi Tanabe Pharma Corp. Preparation of 2-phenyl-2-oxoacetamide oxime derivatives as glucokinase activator for treatment of diabetes, diabetic complication, and obesity. WO2008084873; 2008
40. Tanabe Seiyaku Co., Ltd. Oxime derivatives as glucokinase activating agents and their preparations, pharmaceutical compositions and use in the treatment of diabetes and related diseases. WO2007007886; 2007
41. F. Hoffmann-La Roche AG. Preparation of 3-oxo-3, 9-dihydro-1H-chromeno [2, 3-c]pyrroles as glucokinase activators for treating metabolic diseases. WO2011157682; 2011
42. F. Hoffmann-La Roche AG. Pyrrolidinone as glucokinase activators and their preparation, pharmaceutical compositions and use in the treatment of metabolic disorders. WO2009127546; 2009
43. F. Hoffmann-La Roche AG. Preparation of isoindolinone derivatives as glucokinase activators for treating metabolic diseases. WO2012150202; 2012
44. F. Hoffmann-La Roche A.-G. Isoindolin-1-one glucokinase activators, and their pharmaceutical compositions, preparation, and use in the treatment or prophylaxis of type II diabetes. WO2002048106; 2002
45. Hoffmann-La Roche, Inc. Isatin and oxindole compounds as glucokinase activators and their preparation and use in the treatment of diabetes. US20120142705; 2012
46. Takeda Pharmaceutical Co., Ltd. Method of making azaindazole derivatives. WO2012051450; 2012
47. Takeda San Diego, Inc. Preparation of pyrazolyl amides as glucokinase activators. WO2009140624; 2009
48. Transtech Pharma, Inc. The use of metformin in combination with a glucokinase activator for antidiabetic pharmaceutical compositions. WO2011149945; 2011
49. Novo Nordisk A/S. Preparation of heteroaryl ureas and their use as glucokinase activators. WO2005066145; 2005
50. TransTech Pharma press release Feb 20, 2007: TransTech Pharma, Inc. obtains entire GKA program for diabetes from Novo Nordisk. Available from: http://www.ttpharma.com/PressReleases/2007/20070220TransTechPharmaInc/tabid/195/ Default.aspx [Last accessed 12 February 2014]
51. TransTech Pharma, Inc. Glucokinase activator compositions for the treatment of diabetes and related disorders. WO2013173417; 2013
52. Kowa Co., Ltd. Preparation of spiroindoline compounds for activating glucokinase. WO2013057944; 2013
53. AstraZeneca AB; AstraZeneca UK Ltd. Preparation of a glucokinase activator and pharmaceutical formulations. WO2012007758; 2012
54. Waring MJ, Clarke DS, Fenwick MD, et al. Property based optimisation of glucokinase activators-discovery of the phase IIb clinical candidate AZD1656. Med Chem Comm 2012;3(9):1077-81
55. Pfizer, Inc. 2-(3, 5-Disubstitutedphenyl) pyrimidin-4(3H)-one derivatives as glucokinase activators and their preparation and use in the treatment of diabetes. WO2011158149; 2011
56. Filipski KJ, Guzman-Perez A, Bian J, et al. Pyrimidone-based series of glucokinase activators with alternative donor-acceptor motif. Bioorg Med Chem Lett 2013;23:4571-8
57. Cadila Healthcare Ltd. N-Thiazolyl benzamide derivatives as glucokinase activators and their preparation and use in the treatment of type II diabetes. WO2010150280; 2010
58. Cadila Healthcare Ltd. Substituted benzamide derivatives as glucokinase (GK) activators and their preparation. WO2011013141; 2011
59. Cadila Healthcare Ltd. Novel compounds for treatment for diabetes. IN2012MU01500; 2014
60. Array BioPharma, Inc.; Amgen, Inc. Urea compounds as GKa activators and their preparation. WO2013086397; 2013
61. Zhejiang Beta Pharma, Inc. Preparation of pyridinyloxypyridinylaminobenzene derivatives for use as glucokinase active modulators. WO2012062210; 2012
62. Daiichi Sankyo Co., Ltd. Preparation of 2, 5-disubstituted pyrrole compounds containing oxazoline moiety as glucokinase (GK) activators. JP2012020960; 2012
63. Daiichi Sankyo Co., Ltd. Phenylpyrrole derivative crystal, is preparation, and use for pharmaceutical compositions and preventive or therapeutic agent for diabetes mellitus or glucose intolerance. WO2012147832; 2012
64. Daiichi Sankyo Co., Ltd. Preparation of novel 2-phenylpyrrole derivatives as glucokinase activators. WO2009099080; 2009
65. Daiichi Sankyo Co., Ltd. Preparation of dipyridylamine derivatives as glucokinase-activating agents. WO2012121314; 2012
66. Sanwa Kagaku Kenkyusho Co., Ltd. Preparation of thiophenecarboxamide derivatives for use as glucokinase activators in medicine. WO2011162267; 2011
67. Sanwa Kagaku Kenkyusho Co., Ltd. Preparation of thiophene-carboxamide derivatives as glucokinase activators. WO2010150899; 2010
68. Institute of Materia Medica, Chinese Academy of Medical Sciences. Preparation of thiazole-5-formamide derivatives for treating glucokinase-related diseases. CN102532123; 2012
69. Institute of Materia Medica, Chinese Academy of Medical Sciences. Pyrimidine derivatives as glucokinase activators and their preparation, pharmaceutical compositions and use in the treatment of diseases. CN102558149; 2012
70. Institute of Materia Medica, Chinese Academy of Medical Sciences. Preparation of thiazolidinedione derivatives as dual agonists of glucokinase and peroxisome proliferator-activated receptors. CN102558167; 2012
71. Institute of Materia Medica, Chinese Academy of Medical Sciences. (Aryl)urea derivatives with agonistic activity of GK and PPAR and their preparation, pharmaceutical compositions and use in the treatment of diabetes mellitus. CN102718703; 2012
72. Institute of Materia Medica, Chinese Academy of Medical Sciences. Preparation of arylurea derivatives with agonist activity of GK and PPAR. CN102718727; 2012
73. Institute of Materia Medica, Chinese Academy of Medical Sciences. Preparation of pyrimidyl-thiazolylamine derivatives with GK and PPAR dual agonist activities. CN102786517; 2012
74. Institute of Materia Medica, Chinese Academy of Medical Sciences. Lignin-like compounds with glucose kinase-activating activity. CN102557893; 2012
75. Amgen, Inc. Preparation of sulfonylpiperazine derivatives that interact with glucokinase regulatory protein for the treatment of diabetes and other diseases. WO2012027261; 2012
76. Lloyd DJ, St Jean DJ Jr, Kurzeja RJM, et al. Antidiabetic effects of glucokinase regulatory protein small-molecule disruptors. Nature 2013;504:437-40
77. St. Jean DJ, Ashton KS, Bartberger MD, et al. Small molecule disruptors of the glucokinase-glucokinase regulatory protein interaction: 2. Leveraging structure-based drug design to identify analogues with improved pharmacokinetic profiles. J Med Chem 2014;57(2):325-38
78. Amgen, Inc. Preparation of cyclic sulfonyl compounds that interact with glucokinase regulatory protein for use in treating type 2 diabetes and other diseases. WO2013123444; 2013
79. Amgen, Inc. Preparation of benzodioxepine and benzodioxine compounds that interact with glucokinase regulatory protein for the treatment of diabetes. WO2012138776; 2012
80. Amgen, Inc. Preparation of benzothiophene sulfonamides and related compounds that interact with glucokinase regulatory protein. WO2013173382; 2013
81. Advinus pipeline. Available from: http://www.advinus.com/pipeline.asp [Last accessed 20 March 2014]
82. Array BioPharma news release Aug 7, 2013: Array BioPharma reports financial results for the fourth quarter and full year of fiscal 2013. Available from: http://investor.arraybiopharma.com/phoenix.zhtml?c=123810&p=irol- newsArticle&ID=1845712&highlight= [Last accessed 12 February 2014]
83. Amgen phase 2 trial of AMG 151. Available from: http://www. clinicaltrials. gov/ct2/show/NCT01464437 [Last accessed 12 February 2014]
84. Sj€ostrand M, Ericsson H, Hartford M, et al. Pharmacodynamic effects of the oral glucokinase activator AZD6370 after single doses in healthy volunteers assessed with euglycaemic clamp. Diabetes Obes Metab 2013;15(1):35-41
85. Ericsson H, Roshammar D, Wollbratt M, et al. Tolerability, pharmacokinetics, and pharmacodynamics of the glucokinase activator AZD1656, after single ascending doses in healthy subjects during euglycemic clamp. Int J Clin Pharmacol Ther 2012;50:765-77
86. AstraZeneca AB; AstraZeneca UK Ltd. Preparation of 3-{[5-(azetidin-1- ylcarbonyl)pyrazin-2-yl]loxy}-5-{[(1S)-2-hydroxy-1-methylethyl]oxy} -N-(5-methylpyrazin-2-yl)benzamide monohydrate as activator of glucokinase. WO2011135355; 2011
87. Wilding JPH, Leonsson-Zachrisson M, Wessman C, Johnsson E. Dose-ranging study with the glucokinase activator AZD1656 in patients with type 2 diabetes mellitus on metformin. Diabetes Obes Metab 2013;15:750-9
88. Kiyosue A, Hayashi N, Komori H, et al. Dose-ranging study with the glucokinase activator AZD1656 as monotherapy in Japanese patients with type 2 diabetes mellitus. Diabetes Obes Metab 2013;15:923-30
89. Daiichi-Sankyo pipeline as of Jan 2014. Available from: http://www. daiichisankyo.com/rd/pipeline/pdf/Pipeline-EN.pdf [Last accessed 20 March 2014]
90. Hua Medicine HMS5552 research overview. Available from: http://www. huamedicine.com/research1.htm [Last accessed 20 March 2014]
91. Sarabu R, Bizzarro FT, Corbett WL, et al. Discovery of piragliatin-first glucokinase activator studied in type 2 diabetic patients. J Med Chem 2012;55(16):7021-36
92. Meininger GE, Scott R, Alba M, et al. Effects of MK-0941, a novel glucokinase activator, on glycemic control in insulin-treated patients with type 2 diabetes. Diabetes Care 2011;34(12):2560-6
93. Klapars A, Campos KR, Waldman JH, et al. Enantioselective Pd-catalyzed alpha-arylation of N-Boc-pyrrolidine: the key to an efficient and practical synthesis of a glucokinase activator. J Org Chem 2008;73:4986-93
94. Magnus NA, Braden TM, Buser JY, et al. Development of an enantioselective hydrogenation based synthesis of a glucokinase activator. Org Process Res Dev 2012;16(5):830-5
95. Yamagami T, Moriyama N, Kyuhara M, et al. Scalable synthesis of a nonracemic alpha-arylpropionic acid via ketene desymmetrization for a glucokinase activator. Org Process Res Dev 2014;18(3):437-45
96. Assessing metabolite coverage of LY2608204 human metabolites in chronic rat and dog toxicology studies. Lilly, poster presented at the 15th Annual Land O' Lakes Conference; 10-14 September 2012; Merrimac, WI. Available from: www.xbl.com/uploads/papers-poster-35-3984033172.pdf [Last accessed 12 February 2014]
97. Lilly phase 2 trial of LY2608204. Available from: http://clinicaltrials. gov/ct2/show/NCT01408095 [Last accessed 12 February 2014]
98. Pfizer phase 1 study of two dosing regimens of PF-04937319. Available from: http://www.clinicaltrials.gov/ct2/show/study/NCT01933672 [Last accessed 12 February 2014]
99. Pfizer pipeline as of February 28, 2014. Available from: http://www.pfizer.com/research/science-and-technology/product-pipeline [Last accessed 20 March 2014]
100. Pfizer phase 2 study of PF-04937319 in type 2 diabetics versus sitagliptin. Available from: http://www.clinicaltrials. gov/ct2/show/NCT01475461 [Last accessed 12 February 2014]
101. Pfizer phase 2 study of PF-04937319 versus glimeperide. Available from: http://www.clinicaltrials.gov/ct2/show/NCT01517373 [Last accessed 12 February 2014]
102. Pfizer pipeline as of May 10, 2012. Available from: http://www.pfizer. com/research/science-and-technology/product-pipeline/past-pipelines [Last accessed 12 February 2014]
103. Pfizer pipeline as of Aug 9, 2012. Available from: http://www.pfizer.com/ research/science-and-technology/product-pipeline/past-pipelines [Last accessed 12 February 2014]
104. Pfefferkorn JA, Guzman-Perez A, Litchfield J, et al. Discovery of (S)-6-(3-cyclopentyl-2-(4-(trifluoromethyl)-1H-imidazol-1-yl)propanamido) nicotinic acid as a hepatoselective glucokinase activator clinical candidate for treating type 2 diabetes mellitus. J Med Chem 2012;55(3):1318-33
105. Kazierad DJ, Bergman AJ, Pfefferkorn JA, et al. Pharmacokinetics and pharmacodynamics of PF-04991532, a hepatoselective glucokinase activator (GKA), administered as monotherapy in Japanese and non-Japanese T2DM patients [1050-P]. ADA 73rd Scientific Sessions; 21-25 June 2013; Chicago, IL
106. Kazierad DJ, Pfefferkorn JA, Bergman A, et al. The hepatoselective glucokinase activator, PF-04991532, lowers HbA1c after 12 weeks of dosing in patients with type 2 diabetes [1051-P]. ADA 73rd Scientific Sessions; 21-25 June 2013; Chicago, IL
107. Pfizer phase 2 trial of b.i.d. PF-04991532 in type 2 diabetics. Available from: http://www.clinicaltrials.gov/ct2/show/NCT01338870 [Last accessed 12 February 2014]
108. Pfizer phase 2 trial of q.d. PF-04991532 in type 2 diabetics. Available from: http://www.clinicaltrials.gov/ct2/show/NCT01336738 [Last accessed 12 February 2014]
109. Haynes N-E, Corbett WL, Bizzarro FT, et al. Discovery, structure-activity relationships, pharmacokinetics, and efficacy of glucokinase activator (2R)-3-cyclopentyl-2-(4-methanesulfonylphenyl)-N-thiazol-2-yl-propionamide (RO0281675). J Med Chem 2010;53(9):3618-25
110. Guertin KR. Allosteric activators of glucokinase (GK) for the treatment of type 2 diabetes. In: Ward RA, Goldberg F, editors. RSC drug discovery series No 19: kinase drug discovery. Royal Society of Chemistry; Cambridge, UK: 2011. p. 244-61
111. Qian Y, Corbett WL, Berthel SJ, et al. Identification of RO4597014, a glucokinase activator studied in the clinic for the treatment of type 2 diabetes. ACS Medicinal Chemistry Letters 2013;4(4):414-18
112. Roche 2008 pipeline. Available from: www.roche.com/gb07erd.pdf [Last accessed 12 February 2014]
113. Bachmann S, Fettes A, Lautz C, Scalone M. Glucokinase activator: practical asymmetric hydrogenation and scalable synthesis of an API fragment. Org Process Res Dev 2013;17(11):1451-7
114. F. Hoffmann-La Roche AG. Preparation of glucokinase activator compound. WO2011023706; 2011
115. Takeda R&D pipeline as of February 5, 2014. Available from: http://www.takeda.com/research/pipeline/[Last accessed 12 February 2014]
116. TransTech Pharma press release August 14, 2013: first liver-selective glucokinase activator for type 2 diabetes demonstrates normalized HbA1c and no hypoglycemia in clinical trials. Available from: http://www.ttpharma.com/ PressReleases/2013/20130814TransTechPharmaPressRelease/tabid/253/Default.aspx [Last accessed 12 February 2014]
117. TransTech Pharma diabetes pipeline. Available from: http://www.ttpharma. com/TherapeuticAreas/MetabolicDiseases/Diabetes/tabid/89/Default.aspx [Last accessed 20 March 2014]
118. Zydus Cadila discovery pipeline. Available from: http://www.zyduscadila. com/discovery.html [Last accessed 12 February 2014]